-
FDA Approves Garzuly: A New Biosimilar Option for Insulin Aspart
A New Milestone in Diabetes Care The FDA has officially granted approval for Garzuly (insulin aspart), a significant development for patients managing diabetes. As a biosimilar to NovoLog, Garzuly offers an alternative treatment option for individuals requiring insulin aspart to improve glycemic control. What You Need to Know About Garzuly Biosimilars are designed to be…
-
A Breakthrough in Diabetes Care: Afrezza Approved for Children and Adolescents
A New Chapter for Pediatric Diabetes Management For many families managing diabetes, the daily routine of injections can be a significant source of stress and discomfort. MannKind Corporation has recently reached a major milestone in diabetes treatment: the FDA has officially approved Afrezza (insulin human) inhalation powder for use in children and adolescents with diabetes.…
-
Biomea Fusion | Presenting New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
NASDAQ: BMEA BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 2 diabetes STOCK & PRESS RELEASE INFO